Vanguard Group Inc. Has $199.68 Million Stock Holdings in Arvinas, Inc. (NASDAQ:ARVN)

Vanguard Group Inc. increased its position in Arvinas, Inc. (NASDAQ:ARVN) by 5.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,851,390 shares of the company’s stock after buying an additional 243,167 shares during the quarter. Vanguard Group Inc. owned 7.13% of Arvinas worth $199,683,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also added to or reduced their stakes in the company. RTW Investments LP acquired a new stake in shares of Arvinas in the fourth quarter valued at about $173,427,000. Price T Rowe Associates Inc. MD increased its position in Arvinas by 42.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,832,123 shares of the company’s stock valued at $157,731,000 after purchasing an additional 1,143,452 shares during the period. Avidity Partners Management LP raised its holdings in Arvinas by 14.2% during the 4th quarter. Avidity Partners Management LP now owns 2,985,117 shares of the company’s stock worth $122,867,000 after purchasing an additional 370,157 shares during the last quarter. Bellevue Group AG lifted its position in shares of Arvinas by 18.0% in the 4th quarter. Bellevue Group AG now owns 2,507,731 shares of the company’s stock worth $103,218,000 after purchasing an additional 382,531 shares during the period. Finally, Commodore Capital LP bought a new stake in shares of Arvinas in the 4th quarter valued at $41,160,000. Institutional investors own 95.19% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on ARVN shares. Wedbush reissued an “outperform” rating and set a $57.00 target price on shares of Arvinas in a research note on Wednesday, May 8th. Truist Financial reiterated a “buy” rating and set a $65.00 price target on shares of Arvinas in a report on Monday, March 25th. Wells Fargo & Company decreased their price target on Arvinas from $63.00 to $60.00 and set an “overweight” rating for the company in a report on Thursday, May 9th. Stifel Nicolaus decreased their price target on Arvinas from $72.00 to $68.00 and set a “buy” rating for the company in a report on Wednesday, May 8th. Finally, HC Wainwright reiterated a “buy” rating and set a $87.00 price target on shares of Arvinas in a report on Friday, May 17th. Two analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $61.13.

Arvinas Stock Performance

ARVN stock opened at $24.85 on Wednesday. The business has a 50-day simple moving average of $29.99 and a two-hundred day simple moving average of $37.68. The company has a market capitalization of $1.70 billion, a P/E ratio of -4.19 and a beta of 1.98. Arvinas, Inc. has a 52-week low of $13.57 and a 52-week high of $53.08.

Arvinas (NASDAQ:ARVN) last announced its earnings results on Tuesday, May 7th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.42) by $0.45. The company had revenue of $25.30 million for the quarter, compared to analysts’ expectations of $32.94 million. The firm’s quarterly revenue was down 22.2% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.54) EPS. As a group, sell-side analysts forecast that Arvinas, Inc. will post -4.08 earnings per share for the current fiscal year.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.